Navigation Links
Intrexon Announces Third Quarter Financial Results
Date:11/7/2013

artners with industrial-scale design and development of complex biological systems.  The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells.  We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.

Non-GAAP Financial MeasuresThis press release presents Adjusted EBITDA and Pro Forma Adjusted EBITDA earnings per share, which are non-GAAP financial measures within the meaning of applicable rules and regulations of the Securities and Exchange Commission ("SEC"). For a reconciliation of Adjusted EBITDA to net loss attributable to Intrexon in accordance with generally accepted accounting principles and for a discussion of the reasons why the company believes that these non-GAAP financial measures provide information that is useful to investors see the tables below under "Reconciliation of GAAP to Non-GAAP Measures." Such information is provided as additional information, not as an alternative to our consolidated financial statements presented in accordance with GAAP, and is intended to enhance an overall understanding of our current financial performance.

TrademarksIntrexon, UltraVector, RheoSwitch Therapeutic System, mAbLogix, LEAP and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor StatementSome of the statements made in this press release are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management be
'/>"/>

SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
2. Misonix, Inc. Announces First Quarter Fiscal Year 2014 Financial Results
3. Pro-Dex, Inc. Announces Fiscal 2014 First Quarter Financial Results Conference Call And Webcast
4. DURECT Announces Proposed Public Offering of Common Stock
5. Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting
6. Star Scientific Announces Leadership Transition, Acceleration of Plans for Submission of an IND to FDA for Pharmaceutical Version of Anatabine Compound
7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
8. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
9. PDL BioPharma Announces Third Quarter 2013 Financial Results
10. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
11. Heska Announces Financial Results for the Third Quarter of Fiscal 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
(Date:2/27/2015)...   Synageva BioPharma Corp. (Synageva) (NASDAQ: ... therapeutic products for rare diseases, joins the National ... for Rare Diseases™ (EURORDIS™), The Global Genes Project™, ... Disease Day. On the last day ... other participants conduct special events to raise awareness ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Inc. (NYSE AMEX: ULU),announced today that an Australian ... the Therapeutic Goods Administration approving the marketing of Altrazeal® ... Australia, Kerry P. Gray, President and CEO of ULURU, ... commercialization of Altrazeal®.  Strategically this is an important market ...
... prostate cancer surgeon , Dr. David Samadi often takes ... join the prostate cancer fight overseas. As a ... and hands-on support is a vital part of the growth ... in countries such as the Netherlands, France, Dominican Republic and ...
Cached Medicine Technology:ULURU Inc. Announces Approval to Market Altrazeal® in Australia 2ULURU Inc. Announces Approval to Market Altrazeal® in Australia 3The Prostate Cancer Foundation Builds Momentum in China 2The Prostate Cancer Foundation Builds Momentum in China 3
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be on ... Show, an annual, premier sustainable building event in Tokyo, ... manufacturers of the latest building products, services and technology. ... manufactured by Pioneer Millworks from their Oregon and New ... hotels, retailers, and corporate offices. Nichibi Global , ...
(Date:2/28/2015)... Flagstaff, AZ (PRWEB) February 28, 2015 ... drug and alcohol treatment center , and current student ... State University, has implemented a weekly forum in psychoeducation ... high school in Flagstaff, AZ as part of her ... a big need for support and counseling at the ...
(Date:2/28/2015)... Developers of FCPX plugins and theme ... for Final Cut Pro X entitled FCPX Overlay Chromatic Grunge ... users total control over 6k lens dirt overlays inside Final ... Studios. “FCPX Overlay Chromatic was professionally designed to add level ... FCPX Overlay Chromatic Grunge 6K is a resourceful tool from ...
(Date:2/28/2015)... The World Scout League Commission (WSLC), an organization ... and firefighters, recently announced its decision to host an ... charitable donations for age-related research. The five-kilometer race, which ... on March 29, 2015; registration will start at 2 ... , To participate in the race, runners have ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2
... found after 36 samples of blood serum of the suspected ... officials said today. // ,Of the 36 samples ... the rest were of viral Encephalitis, said A K Rathi, ... ,Rathi said since April 1, 171 patients were admitted ...
... The prevalence of HIV virus in South Africa may be ... HIV and Syphilis Antenatal Sero-prevalence Survey for 2005 // that ... they had been in 2004 (29.5 per cent) and in ... said today while the latest finding was 'encouraging', there was ...
... received approval from the Drugs Controller General (India) (DCGI) ... LL-42 18 (Desoside-P).// ,The company received permission ... pure compound, LL-42 18, after DCGI found the clinical ... ,Lupin informed the Bombay Stock Exchange that it ...
... promise for a large number of Alzheimer's patients, a breakthrough ... designed to be implanted under// the skin on the abdomen. ... that is slowly pumped into the patient's blood stream. According ... the medicine is capable of retarding the progress of the ...
... panel investigating the incidence of breast cancer at Brisbane's ABC ... panel.// ,ABC managing director Mark Scott said that ... the panel chaired by Dr Bruce Armstrong. ,Mr ... established to work alongside the panel. ,The review ...
... in Aberdeen's police lockups are to be offered immediate access ... ,This scheme is already underway in many areas of ... Edinburgh. ,Funding has been provided to continue this ... in Aberdeen. ,Under this scheme the users ...
Cached Medicine News:Health News:Breast Cancer Review Panel Adds Two Experts 2
... the pain and hassle of testing. Unlike ... device is the only one with a ... testing, with less hassle and improved safety. ... and no side-to-side motion for less skin ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
Medicine Products: